Study detail
RecruitingPhase 2
Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Glaukos Corporation
Summary
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- No
Detailed criteria
Inclusion Criteria: * Be ≥ 18 and ≤ 55 years of age * Diagnosis of keratoconus in the study eye Exclusion Criteria: * Pregnant, lactating or planning a pregnancy * Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial
Interventions
- DrugGLK-221 Ophthalmic Solution
GLK-221 Ophthalmic Solution administered twice daily to both eyes
- DrugPlacebo Ophthalmic Solution
Placebo Ophthalmic Solution administered twice daily to both eyes
Location
- Glaukos Clinical Study SiteWesterville, Ohio